Aurobindo Pharma arm Curateq Biologics incorporates new wholly owned subsidiary in Netherlands

Published On 2025-05-29 11:26 GMT   |   Update On 2025-05-29 11:26 GMT

Hyderabad: Aurobindo Pharma has announced that Curateq Biologics Private Limited, a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary in the Netherlands by the name of CuraTeQ Biologics B.V.

The move is aimed at expanding the company's Biopharma Products business in Europe.

According to the disclosure, CuraTeQ Biologics B.V. was incorporated on May 28, 2025. 

Advertisement

"Initial subscription to the share capital of EURO 10,000 divided into 10000 shares with a nominal value of EURO 1.00 each," the company said in a BSE filing.

No government or regulatory approvals were required for the incorporation.

Medical Dialogues had earlier reported that CuraTeQ Biologics s.r.o., had received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation of Dazublys (150 mg powder for concentrate for solution for infusion), its trastuzumab biosimilar, for the treatment of HER2-positive metastatic and early breast cancers.

Read also: Aurobindo Pharma arm CuraTeQ Biologics gets positive opinion for breast cancer drug Dazublys from EMA

CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Limited, is a global biopharmaceutical company headquartered in Hyderabad, India. The company is focused on developing biosimilars for the treatment of various cancers and autoimmune diseases. CuraTeQ's pipeline consists of fourteen biosimilars, primarily targeting the immunology and oncology segments. It has end-to-end capabilities in producing a full range of products from bulk drug substance to fill-finish and packaged drug products.

Read also: Aurobindo Pharma arm CuraTeQ Biologics completes successful Phase 1 Pharmacokinetics study of bone drug





Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News